Quarterly Consolidated Statement Of Cash Flows

TAKARA BIO INC. - Filing #7256073

Concept 2024-04-01 to
2025-03-31
As at
2025-03-31
2024-04-01 to
2025-03-31
2023-04-01 to
2024-03-31
As at
2024-03-31
2023-04-01 to
2024-03-31
As at
2023-03-31
Quarterly consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
217,000,000 JPY
1,997,000,000 JPY
2,853,000,000 JPY
3,515,000,000 JPY
Depreciation
3,611,000,000 JPY
4,279,000,000 JPY
Impairment losses
377,000,000 JPY
207,000,000 JPY
Amortization of goodwill
690,000,000 JPY
640,000,000 JPY
Increase (decrease) in allowance for doubtful accounts
-2,000,000 JPY
-53,000,000 JPY
Interest expenses
20,000,000 JPY
23,000,000 JPY
Decrease (increase) in trade receivables
-2,250,000,000 JPY
1,501,000,000 JPY
Decrease (increase) in inventories
102,000,000 JPY
-324,000,000 JPY
Increase (decrease) in trade payables
-42,000,000 JPY
-928,000,000 JPY
Other, net
-88,000,000 JPY
-114,000,000 JPY
Subtotal
5,576,000,000 JPY
4,361,000,000 JPY
Interest and dividends received
285,000,000 JPY
166,000,000 JPY
Interest paid
-20,000,000 JPY
-22,000,000 JPY
Net cash provided by (used in) operating activities
5,844,000,000 JPY
1,711,000,000 JPY
Cash flows from investing activities
Other, net
1,000,000 JPY
-19,000,000 JPY
Net cash provided by (used in) investing activities
-10,912,000,000 JPY
-13,043,000,000 JPY
Cash flows from financing activities
Dividends paid
-2,048,000,000 JPY
-5,052,000,000 JPY
Other, net
0 JPY
JPY
Net cash provided by (used in) financing activities
-2,256,000,000 JPY
-5,233,000,000 JPY
Effect of exchange rate change on cash and cash equivalents
1,190,000,000 JPY
678,000,000 JPY
Net increase (decrease) in cash and cash equivalents
-6,134,000,000 JPY
-15,886,000,000 JPY
Cash and cash equivalents
27,036,000,000 JPY
33,171,000,000 JPY
49,058,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.